-
-
-
-
-
-
-
Genmab reports $3.96 billion in DARZALEX sales for first quarter 2026
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Raised to $40 at H.C. Wainwright
-
-
-
-
-
-
-
Genmab A/S (GMAB) resumes trading
-
-
-
-
-
-
-
Genmab receives FDA approval for EPKINLY combination in follicular lymphoma
-
-
-
-
-
-
-
Genmab A/S (GMAB) PT Raised to $39 at Leerink Partners
-
-
-
-
-
-
-
Guggenheim Upgrades Genmab A/S (GMAB) to Buy
-
-
-
-
-
-
-
Genmab A/S (GEN:DC) (GMAB) PT Lowered to DKK2,000 at RBC Capital on Fx Reset
-
413,534 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

